MARKET

ATNFW

ATNFW

180 Life Sciences Corp.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4599
+0.0099
+2.20%
Opening 09:33 01/27 EST
OPEN
0.4599
PREV CLOSE
0.4500
HIGH
0.4599
LOW
0.4599
VOLUME
100
TURNOVER
--
52 WEEK HIGH
2.970
52 WEEK LOW
0.3400
MARKET CAP
--
P/E (TTM)
-0.4852
1D
5D
1M
3M
1Y
5Y
180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022
PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory di...
GlobeNewswire · 12/28/2021 16:00
BRIEF-180 Life Sciences Says Entered Into New Licensing Agreement With University Of Oxford
reuters.com · 12/15/2021 13:20
180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases
PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory di...
GlobeNewswire · 12/15/2021 13:15
Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares
Investors who take an interest in 180 Life Sciences Corp. ( NASDAQ:ATNF ) should definitely note that the Lead...
Simply Wall St. · 12/12/2021 11:06
180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares
CEO of 180 Life Sciences Corp (30-Year Financial, Insider Trades) James N. Woody (insider trades) bought 12,500 shares of ATNF on 12/09/2021 at an average price of $4.27 a share.
GuruFocus.com · 12/10/2021 22:15
BRIEF-180 Life Sciences Provides Follow-Up Information On Oxford University And The Company’S Successful Dupuytren’S Phase 2B Clinical Trial Results
reuters.com · 12/06/2021 14:41
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results
PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory di...
GlobeNewswire · 12/06/2021 13:15
180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial
‘Cellular and Molecular Profiling of Dupuytren’s Disease: From the Lab to the Clinic’ Presented Wednesday, December 1, 2021, at 3pm ESTPALO ALTO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “...
GlobeNewswire · 12/01/2021 19:45
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNFW. Analyze the recent business situations of 180 Life Sciences Corp. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+1.60%
Key Executives
Chairman/Independent Director
George Hornig
Chief Executive Officer/Director
Marlene Krauss
Chief Operating Officer/Director
Joseph Williamson
Director
Larry Gold
Independent Director
Sherrill Neff
Independent Director
Andrew Sherman
No Data
About ATNFW
180 Life Sciences Corp., (180 Life Sciences) formerly KBL Merger Corp. IV., is a research and development company. The Company is focused on research into solving one of the diseases is inflammation. The Company consists of three programs developing drugs in separate areas of inflammation. The Company’s pipeline, including Fibrosis and Anti-TNF, SCAs and a7nAChR. The Fibrosis and Anti-TNF treats diseases like Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), nonalcoholic steatohepatitis (NASH). The SCAs includes chronic pain and early arthritis. The a7nAChR includes smoking cessation induced ulcerative colitis.

Webull offers kinds of 180 Life Sciences Corp stock information, including NASDAQ:ATNFW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNFW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNFW stock methods without spending real money on the virtual paper trading platform.